1. Li, Linzhi, Jiang, Pengcheng, Hu, Weimin, Ning, Jinzhuo, Cheng, Fan. 2024. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. In Journal of translational medicine, 22, 295. doi:10.1186/s12967-024-05099-6. https://pubmed.ncbi.nlm.nih.gov/38515112/
2. Gao, Xiaoyan, Jiang, Aigui, Shen, Yahui, Lu, Huiyu, Chen, Rong. . Expression and clinical significance of AURKB gene in lung adenocarcinoma: Analysis based on the data-mining of bioinformatic database. In Medicine, 100, e26439. doi:10.1097/MD.0000000000026439. https://pubmed.ncbi.nlm.nih.gov/34397793/
3. Zhu, Guoqing, Luo, Laihui, He, Yongzhu, Hu, Zhigao, Shan, Renfeng. 2024. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway. In Molecular carcinogenesis, 63, 1814-1826. doi:10.1002/mc.23775. https://pubmed.ncbi.nlm.nih.gov/38874176/
4. Joshi, Sunil K, Nechiporuk, Tamilla, Bottomly, Daniel, Druker, Brian J, Traer, Elie. 2021. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. In Cancer cell, 39, 999-1014.e8. doi:10.1016/j.ccell.2021.06.003. https://pubmed.ncbi.nlm.nih.gov/34171263/
5. Yang, Yonglin, Sheng, Ying, Sun, Dahong, Li, Li, Sun, Lizhi. 2023. AURKB promotes tumorigenesis and carboplatin resistance by regulating the ERK pathway in neuroblastoma cells. In The International journal of neuroscience, 133, 1224-1232. doi:10.1080/00207454.2021.1914610. https://pubmed.ncbi.nlm.nih.gov/34396896/